San Francisco, CA, United States of America

Kenneth J Hillan

This inventor holds 65 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 18 EPO patents, primarily in Tumor Treatment (CPC class C12N). Top assignees: Genentech, Inc., Genetech, Inc.. Active years: 2000-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth J Hillan. Retrieved from https://idiyas.com/inventor/kenneth-j-hillan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 65 (Patent Applications = 11)

% Patents Active = 63.1

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 12)

Average Co-Inventor Count = 8.0

ph-index = 14

Forward Citations = 585(Granted Patents)

Forward Citations (Not Self Cited) = 576(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Years Active: 2000-2014

Loading Chart...

Areas of Expertise:

Tumor Treatment

Antibody Therapies

IL-17 Receptor

Liver Protection

Therapeutic Uses

Nucleic Acids

Polypeptides

Immune Diseases

Diagnosis Methods

Hepatic Disorders

Pharmaceutical Compositions

Anti-IL-17 Antibodies

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8728480 - Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof (2014-05-20),

2. 8350008 - WISP polypeptides and nucleic acids encoding same (2013-01-08),

3. 8338132 - Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof (2012-12-25),

4. 8278042 - Compositions and methods for the diagnosis and treatment of tumor (2012-10-02),

5. 8273703 - IL-17 receptor-like polypeptides and therapeutic uses thereof (2012-09-25),

6. 8034342 - Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E (2011-10-11),

7. 7951546 - Compositions and methods for the diagnosis and treatment of tumor (2011-05-31),

8. 7939268 - Compositions and methods for the diagnosis and treatment of tumor (2011-05-10),

9. 7803915 - Antibody compositions for the diagnosis and treatment of tumor (2010-09-28),

10. 7749504 - Anti-TAT188 antibodies (2010-07-06),

11. 7709455 - Compositions and methods for liver growth and liver protection (2010-05-04),

12. 7700571 - Compositions and methods for liver growth and liver protection (2010-04-20),

13. 7619062 - PRO214 polypeptides (2009-11-17),

14. 7557192 - Anti-PRO335 antibodies (2009-07-07),

15. 7470771 - Secreted and transmembrane polypeptides and nucleic acids encoding the same (2008-12-30),

Title: The Innovative Contributions of Kenneth J. Hillan

Introduction

Kenneth J. Hillan is a prominent inventor based in San Francisco, CA, known for his significant contributions to biomedical research and innovation. With a prolific portfolio of 65 patents, he has made impactful strides in the field of tumor treatment and related technologies. His work not only reflects his expertise but also contributes significantly to advancements in medical science.

Latest Patents

Hillan's latest patents demonstrate his ongoing commitment to pioneering healthcare solutions. One of his key inventions is titled "Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof." This invention focuses on novel compositions of matter aimed at diagnosing and treating tumors in mammals, highlighting innovative approaches to cancer therapy. Another important patent is "WISP polypeptides and nucleic acids encoding same," which involves Wnt-1-Induced Secreted Proteins (WISPs) and their encoding genes. This patent provides insights into producing specific polypeptides and antibodies, thus fostering new avenues for treatment methodologies in the field of oncology.

Career Highlights

Throughout his career, Hillan has held significant positions at notable companies such as Genentech, Inc. and Genetech, Inc., where his research and innovations have been pivotal in advancing therapeutic strategies. His dedication to developing groundbreaking treatments has established him as a thought leader in the industry, paving the way for future innovations.

Collaborations

Hillan has collaborated with esteemed colleagues in his domain, including Audrey Goddard and Austin L. Gurney. These collaborations not only enhance the quality of his research but also strengthen the overall impact of his inventions within the scientific community.

Conclusion

Kenneth J. Hillan is a remarkable inventor whose contributions to the field of medicine continue to make significant impacts. His extensive patent portfolio and collaborations with leading professionals underscore his influence and commitment to innovation. As the healthcare landscape evolves, Hillan's inventions will likely play a crucial role in shaping future medical treatments, particularly in oncology.

Profile summary based on public USPTO records.